D
Downing Ventures, est. 1986 (VCT/EIS arm 2014+), early-stage investor within Downing LLP. Post-2022 refocus: healthcare-only thesis. ~36-90 portfolio cos (pre/post-divestment). Team: 9 incl. 2 partners. AUM undisclosed. Key exits: Ayar Labs, Touchlight (unicorns), Destiny Pharma, Hubble (Jan 2025). Strong sector expertise, active portfolio support.
Check Size
£500K - £5M
Investment Focus
SectorHealth & Life Sciences
OtherEIS/SEIS Eligible
Investment Thesis
Healthcare focus post-2022 strategic pivot. Seed-Series A. £500k-£5m cheques. UK-concentrated (Cambridge, Oxford, London, Bristol/Bath). VCT/EIS-backed. Targets innovation, deep-science, digital health. Avoids: non-healthcare tech (divested to Foresight June 2022). Strong track record: 2 unicorns, 8 exits, 1 IPO.
Interested in connecting?
Visit their website or reach out directly.